ITEMS IN AFP WITH KEYWORD:
Aug 15, 2005 Issue
AHRQ Releases Evidence Report on Managing Menopause-Related Symptoms [Practice Guidelines]
The Agency for Healthcare Research and Quality (AHRQ) has released the results of a systematic review on managing menopause-related symptoms. The report evaluates the benefits and harms of common interventions to relieve menopause-related symptoms.
Jul 15, 2005 Issue
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women [U.S. Preventive Services Task Force]
This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on hormone therapy for the prevention of chronic conditions in post-menopausal women and the supporting scientific evidence and updates the Task Force’s 2002 recommendations on hormone replacement therapy.
The North American Menopause Society (NAMS) has released an evidence-based position statement on the treatment of vasomotor symptoms associated with menopause to provide recommendations on the most effective treatments.
The herb black cohosh, or Actaea racemosa (formerly named Cimicifuga racemosa), is native to North America. The roots and rhizomes of this herb are widely used in the treatment of menopausal symptoms and menstrual dysfunction. Studies have demonstrated that this botanic medicine, when standardized p...
Night sweats are a common outpatient complaint, yet literature on the subject is scarce. Tuberculosis and lymphoma are diseases in which night sweats are a dominant symptom, but these are infrequently found to be the cause of night sweats in modern practice. While these diseases remain important dia...
Jan 15, 2003 Issue
Postmenopausal Hormone Replacement Therapy for the Primary Prevention of Chronic Conditions [U.S. Preventive Services Task Force]
These are the current U.S. Preventive Services Task Force (USPSTF) recommendations for use of hormone replacement therapy (HRT) for the primary prevention of chronic conditions in postmenopausal women.
With growing concern about the use of hormone replacement therapy, some women are looking for alternative treatments for menopausal symptoms and preventing postmenopausal cardiovascular disease and osteoporosis. In observational trials, exercise has been associated with decreased vasomotor symptoms....
Many women will spend one third of their lifetime after menopause. A growing number of options are available for the treatment of menopausal symptoms like vasomotor instability and vaginal atrophy, as well as the long-term health risks such as cardiovascular disease and osteoporosis that are associa...
Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically ob...